Skip to main content

Table 1 Characteristics of studies included in the final meta-analysis of Ki-67 expression and prognosis of lymphoma

From: Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis

First author Year Country Patient (P/N) Age (year) Disease subtype High Ki-67 expression threshold Antibody Sample source Therapy regimen HR (95% CI) of OS HR (95% CI) of DFS Quality score Study type
Salek 2013 [40] Czech 210 (74/136) NA MCL 30% (estimated) Anti-MIB-1 WTS From no chemotherapy to intensive induction with or without ASCT 2.05 (1.45-2.89) NA 7 R
          R-treated 2.63 (1.72-4.04) NA   
Li 2013 [5] America 43 (18/25) 46 median NK/TL 60% (image analysis) Anti-Ki-67 WTS CHOP + RT mostly 5.15 (1.52-17.58) 3.43 (1.1-10.72) 6 R
Geisler 2012 [6] Europe 122 (33/89) 56 median MCL 33% (estimated) NA NA R-CHOP/R-AraC + ASCT 2.64 (1.46-4.77) 2.32 (1.39-3.89) 7 p
Li 2012 [7] China 118 (55/63) 53 median DLBCL 70% (estimated) Anti-Ki-67 WTS R-CHOP + RT 1.284 (1.075-1.535) 3.38 (1.64-6.93) 8 R
Salles 2011 [19] Europea and America 1138 (627/511) NA DLBCL 75% (estimated) NA TMAs R-CHOP 1.8 (1.1-2.9) NA 8 p
          CHOP 1 (0.6-1.5) NA   
Gaudio 2011 [20] Italy 111 (38/73) 60 median DLBCL 80% (estimated) NA WTS R-CHOP 2.1 (1.6-4.8) 2.6 (1.2-3.8) 6 R
          CHOP 2.1 (0.9-4.3) NA   
Song 2011 [21] Korea 65 (31/34) 59 median DLBCL 70% (estimated) Anti-Ki-67 WTS HD-MTx + WBRT 1.657 (0.893-3.259) NA 5 R
Ott 2010 [22] Europe 386 (283/103) 68 median DLBCL 75% (estimated) Anti-MIB-1 TMAs R-CHOP 0.8 (0.4-1.5) 0.8 (0.5-1.4) 7 P
          CHOP 1.1 (0.6-1.9) 0.9 (0.5-1.4)   
Barros 2010 [23] Germany 87 (53/34) 14 median HL 50% (image analysis) Anti-MIB-1 TMAs ABVD + RT NA NA 7 R
Goy 2010 [8] Europea and America 67 (16/51) 66 median MCL 50% (estimated) Anti-Ki-67 WTS Bortezomib 1.93 (0.9-4.1) NA 5 P
Yoon 2010 [24] Korea 144 (46/98) 54 median DLBCL 85% (estimated) Anti-Ki-67 WTS R-CHOP + partial RT 2.876 (0.972-8.508) 2.9 (1.26-6.7) 9 P
Chung 2010 [25] Canada 80 (22/58) 64 median MCL 50% (estimated) Anti-Ki-67 WTS CHOP mostly 4.4 (2.24-8.64) NA 4 R
Garcia 2008 America 76 (38/38) 62 median MCL 20% (estimated) Anti-Ki-67 WTS R-hyper-CVAD NA NA 9 P
His 2008 America 52 (17/35) 56 median MCL 35% (estimated and image analysis) Anti-Ki-67 WTS R-CHOP + ASCT NA 2.46 (1.14-5.31) 9 P
Hasselblom 2008 [10] Sweden 199 (149/50) 66 median DLBCL 49% (image analysis) Anti-Ki-67 WTS CHOP/CHOP like + partial RT 0.625 (0.256-1.11) NA 8 P
Szczuraszek 2008 [28] Poland 53 (24/29) 56.3 mean NHL 30% (image analysis) Anti-MIB-1 WTS NR 2.567 (1.144-5.761) NA 6 R
Determann 2008 [29] Europe 249 (nr) NA MCL 10% (estimated) Anti-MIB-1 or Ki-S5 NA CHOP or MCP or R-CHOP 1.27 (1.15-1.39) NA 6 P
Kim 2007 [30] Korea 50 (27/23) 41 median NK/TL 65% (estimated) Anti-MIB-1 WTS CHOP + partial RT 4.33 (1.108-16.918) 3.23 (1.07-9.72) 8 R
Bahnassy 2006 [31] Egypt 50 (35/15) 45 median NHL 30% (estimated) Anti-MIB-1 WTS CHOP + partial RT 0.696 (0.274-1.766) NA 7 R
Jerkeman 2004 [9] Europe 185 (69/116) NA DLBCL 60% (estimated) Anti-MIB-1 WTS CHOP or M-BACOP 0.56 (0.3-1) 0.53 (0.31-0.91) 5 P
Martinez 2004 [32] Spain 80 (nr) NA MCL 50% (estimated) Anti-MIB-1 WTS NA 4.4 (1.9-9.9) NA 4 R
Seki 2003 [33] Japan 27 (14/13) 59.7 mean DLBCL 40% (estimated) Anti-Ki-67 WTS CHOP   NA 6 R
Provencio 2003 [34] Spain 42 (nr) 29mean HL 20% (NA) NA WTS MOPP or ABVD 3.3 (0.85-12.5) 2.21 (0.92-5.33) 4 R
Raty 2002 [35] Finland 96 (31/65) NA MCL 26% (estimated) Anti-Ki-67 WTS CHOP or M-BACOD mostly + partial RT and SCT 3.25 (1.9-5.58) NA 5 R
Sanchez 1998 [36] Spain 77 (36/41) 62 median DLBCL 20% (image analysis) Anti-MIB-1 WTS CHOP + partial RT or surgery 1.74 (1.064-2.848) 1.06 (0.48-2.33) 6 R
Morente 1997 [37] Spain 140 (nr) NA HL Continuous variable (image analysis) Anti-MIB-1 WTS MOPP or ABVD + RT 1.04 (1–1.08) NA 4 R
Miller 1994 [38] America 60 (11/49) NA DLBCL 80% (estimated) Anti-Ki-67 WTS CHOP, M-BACOD, ProMACE-CytaBOM, or M-BACOP 5.9 (2.2-16.1) NA 8 P
Slymen 1990 [39] America 105 (19/86) 58 median DLBCL 60% (estimated) Anti-Ki-67 WTS CHOP, M-BACOD, ProMACE-CytaBOM, CVP or M-BACOP + partial RT or surgery 3.64 (1.66-7.95) NA 8 R
  1. P/N, the number of positive/negative; NK/TL. NK/T cell lymphoma; MCL, mantle cell lymphoma; DLBCL, difftuse largeB-cell lymphoma; NHL, Non Hodgkin Lymphoma; HL, Hodgkin Lymphoma; NA, not availiable; WTS, whole tissue sections; TMAs, tissue microarrays; HR, hazard ratio; 95CI%, 95% confidence interval; OS, overall survival; DFS, disease free survival; P, prospective; R, retrospective; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; RT, radiotherapy; ASCT, autologous stem cell transplantation; WBRT, Whole Brain Radiotherapy; ABVD, adriamycin, bleomycin, vinblastine, and dacarbazine; R-hyper-CVAD, rituximab plus hyperfractioned cyclophosphamide, vincristine, doxorubicin, and dexamethasone; MCP, mitoxantrone, chlorambucil, and prednisone; M-BACOD(P), methotrexate, bleomycin, doxorubicin, cyclophospha-mide, vincristine, dexamethasone (prednisone); MOPP, mechlorethamine, vincristine, procarbazine, and prednisone; ProMACE-CytaBOM, doxorubicin, cyclophosphamide, etopo-side, cytarabine, bleomycin, vincristine, methotrexate with leucovorin rescue, and prednisone.